The U.S. Food and Drug Administration approved a genetic enoxaparin sodium injection used to prevent blood clotting.

The genetic version of the blood thinner drug Lovenox manufactured by Sanofi-Aventis will be cheaper than the brand versions made from the German pharmaceutical company Momenta Pharmaceuticals Inc.

Lovenox is an anti-coagulant drug that comes in an injectable format and works to prevent blood clots and vein thrombosis by thinning the blood inside the body.

The FDA commented that the approval for the genetic drug was complex because it had to demonstrate that it contains the same active ingredient of the brand-name drug. The main ingredient in the drug is heparin, a mixture of naturally-derived sugar molecules. ‘

Lovenox is the second best selling drug by the company and share in the company rose nearly 80 percent after the FDA’s approval.